Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration, is characterized by polypoidal lesions and abnormal branching vascular network seen on indocyanine green angiography (ICGA). In addition to visual acuity (VA) outcomes, complete polypoidal regression (CPR) is considered an important anatomical outcome in PCV studies [1, 2]. However, limited information exists regarding correlations between CPR and VA outcomes in PCV.
This retrospective cohort study, approved by Ethical Committees and Institutional Review Boards at each study site, adhered to the tenets of the Declaration of Helsinki. Adult PCV patients treated at 3 centers in Thailand (Chiang Mai University Hospital, Prince of Songkla University Hospital, and Rajvithi Hospital) between January 1, 2015 and December 31, 2018 were identified. Inclusion criteria included: (1) treatment-naïve PCV, (2) subsequent aflibercept monotherapy for ≥1 year, (3) VA and ICGA done at baseline, 3 months and 12 months.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Change institution
Buy or subscribe
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: Case example showing incomplete polypoidal regression after treatment not necessarily correlated with final visual acuity.
References
Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, et al. PLANET Investigators Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol. 2019;204:80–9.
ArticleCASPubMedGoogle Scholar
Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. EVEREST II Study Group Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138:935–42.
ArticlePubMedPubMed CentralGoogle Scholar
Morizane-Hosokawa M, Morizane Y, Kimura S, Shiode Y, Hirano M, Doi S, et al. Impact of polyp regression on 2-year outcomes of intravitreal aflibercept injections: a treat-and-extend regimen for polypoidal choroidal vasculopathy. Acta Med Okayama. 2018;72:379–85.
CASPubMedGoogle Scholar
Cho JH, Park YJ, Cho SC, Woo SJ. Posttreatment polyp regression and risk of massive submacular hemorrhage in eyes with polypoidal choroidal vasculopathy. Retina. 2020;40:468–76.
ArticleCASPubMedGoogle Scholar
Kimura M, Sakurada Y, Fukuda Y, Matsubara M, Kotoda Y, Kasai Y, et al. Association of polyp regression after loading phase with 12-month outcomes of eyes with polypoidal choroidal vasculopathy. Pharmaceuticals. 2024;17:687.
ArticleCASPubMedPubMed CentralGoogle Scholar
Download references
Funding
Unrestricted research funds to the Johns Hopkins University School of Medicine for Macular Degeneration and Related Diseases Research. (The sponsor of this funding, Johns Hopkins University School of Medicine, had no role in the design or conduct of this research.)
Author information
Authors and Affiliations
Retina Division, Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Voraporn Chaikitmongkol, Janejit Choovuthayakorn, Direk Patikulsila, Nawat Watanachai & Paradee Kunavisarut
Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Patcharawan Chatromyen
Retina Division, Department of Ophthalmology, Faculty of Medicine, Rajvithi hospital, Rangsit University, Bangkok, Thailand
Paisan Ruamviboonsuk
Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
Pichai Jirarattanasopa, Mansing Ratanasukon & Patama Bhurayanontachai
Retina Division, Department of Ophthalmology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Nawat Watanachai
Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Neil M. Bressler
Authors
Voraporn Chaikitmongkol
View author publications
You can also search for this author in PubMedGoogle Scholar
2. Patcharawan Chatromyen
View author publications
You can also search for this author in PubMedGoogle Scholar
3. Janejit Choovuthayakorn
View author publications
You can also search for this author in PubMedGoogle Scholar
4. Direk Patikulsila
View author publications
You can also search for this author in PubMedGoogle Scholar
5. Paisan Ruamviboonsuk
View author publications
You can also search for this author in PubMedGoogle Scholar
6. Pichai Jirarattanasopa
View author publications
You can also search for this author in PubMedGoogle Scholar
7. Nawat Watanachai
View author publications
You can also search for this author in PubMedGoogle Scholar
8. Paradee Kunavisarut
View author publications
You can also search for this author in PubMedGoogle Scholar
9. Mansing Ratanasukon
View author publications
You can also search for this author in PubMedGoogle Scholar
10. Patama Bhurayanontachai
View author publications
You can also search for this author in PubMedGoogle Scholar
11. Neil M. Bressler
View author publications
You can also search for this author in PubMedGoogle Scholar
Contributions
VC: study design, data analysis, manuscript draft; PC: data collection, manuscript draft; JC: data analysis, manuscript revision; DP: data collection, manuscript revision; PR: data collection, manuscript revision; PJ: data collection, manuscript revision; NW: data collection, manuscript revision; PK: data collection, manuscript revision; MR: data collection, manuscript revision; PB: data collection, manuscript revision; NB: study design, data analysis, manuscript revision.
Corresponding author
Correspondence to Neil M. Bressler.
Ethics declarations
Competing interests
NB reported grants to his institution, the Johns Hopkins University School of Medicine, from Regeneron outside the submitted work, and grants to his spouse’s institution, the Johns Hopkins University School of Medicine, from Boehringer Ingelheim outside the submitted work; all other authors had no conflict of interest related to this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Chaikitmongkol, V., Chatromyen, P., Choovuthayakorn, J. et al. Correlation between complete polypoidal regression and visual outcomes in polypoidal choroidal vasculopathy eyes receiving intravitreal aflibercept. Eye (2025). https://doi.org/10.1038/s41433-025-03750-0
Download citation
Received:06 September 2024
Revised:13 December 2024
Accepted:28 February 2025
Published:14 March 2025
DOI:https://doi.org/10.1038/s41433-025-03750-0
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative